Dabogratinib
Phase 2Small molecule
Dabogratinib is one of 45 small molecule programs targeting Upper Tract Urothelial Carcinoma. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Urothelial Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Gemzar
Johnson & JohnsonPhase 3
Tecentriq
RochePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxol
TevaPhase 3
Beyfortus
BeiGenePhase 3
Paraplatin
AAvyxa
Phase 3
Folvite
Eli LillyPhase 3
Vectibix
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dabogratinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTyra Biosciences, Inc